Mr. Pitts (for himself, Mr. Pallone, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
To amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufacturers and distributors seeking to conduct clinical testing.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. Improving Regulatory Transparency for New Medical Therapies Act. H.R. 639. 114th
Cong., 1st
sess., Introduced in House February 2, 2015. https://www.govinfo.gov/app/details/BILLS-114hr639ih.
APA
Congress, House of Representatives (2015, February 2). Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-114hr639ih.
MLA
United States, Congress, House of Representatives. Improving Regulatory Transparency for New Medical Therapies Act. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-114hr639ih. 114th Congress, H.R. 639, Introduced in House 2 Feb. 2015.
Bluebook
H.R.639 - 114th Congress (2015-2016): Improving Regulatory Transparency for New Medical Therapies Act, H.R.639, 114th Cong. (2015), https://www.govinfo.gov/app/details/BILLS-114hr639ih.
